Fact CheckerSign in

NCT06601140Recruiting

Evaluation of the Concordance Between Measures Obtained by a Medical Device for Emotional Monitoring (EMOCARE) and the Patient Health Questionnaire (PHQ-9) Score in Patients With Mild to Severe Depressive Episode

Evaluation of the Concordance Between Measures Obtained by a Medical Device for Emotional Monitoring (EMOCARE) and the Patient Health Questionnaire (PHQ-9) Score in Patients With Mild to Severe Depressive Episode: Prospective, Multicentric, Comparative, Single Blind Clinical Investigation. EMC1 Study

Source: ClinicalTrials.gov · Last updated 19 Feb 2026

Brief summary (registry, in English)

The aim of this clinical investigation is to find out whether the EMOCARE emotional monitoring software provides consistent results compared with the tools available for assessing the emotional state of patients suffering from mild to moderately severe depressive episod. It will also provide information on how patients feel about the use of passive monitoring software (without the active involvement of patient). The main questions it aims to answer are as follows: Does EMOCARE provide consistent results compared with tools already used in current practice? What are the medical problems encountered by participants when using EMOCARE? The researchers will compare EMCOCARE to various questionnaires usually used in the management of patients suffering from depression (PHQ-9, MADRS, GAD-7, BDI-II, EQ-5D-5L). Participants who agree to take part in the study, during a selection visit, will be able to: 1. Install the software on a digital interface (smartphone, computer, etc.) and activate or deactivate it whenever they wish during the 6-week follow-up period. 2. Attend 2 scheduled appointments at the centre (a first appointment then a second 6 weeks later) to complete a series of questionnaires, being questioned by the doctor, and fill in other questionnaires on their own. 3. At home, answer questionnaires independently, 2 weeks and 4 weeks after the first appointment. 4. Receive a telephone call from the doctor 3 weeks after the first appointment to find out how the participants are feeling. 5. Keep a diary with the symptoms they have experienced, any medical consultations they have made, or changes in drug treatment.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
104 (estimated)
First submitted
9 Sept 2024
Start date
5 Mar 2025
Primary completion date
4 Feb 2027
Lead sponsor
Emobot
Diseases
Depression
NCT number
NCT06601140

What you commit to

  • Study type: Interventional
  • Planned participants: 104
  • From 5 Mar 2025 to the primary completion date, 4 Feb 2027
  • 11 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patient treated with antipsychotic drugs.

Other illness

  • Patients with borderline personality disorders.

Age

  • Woman of childbearing age without effective contraception.

Other

  • Patient with an unstable pathology that could interfere with the study.
  • Patient unable to communicate or cooperate with the investigator due to a low mental level, language difficulties or impaired cerebral function.
  • Patient with an active suicidal tendency or patient who has had a suicidal episode in the last 6 months
  • Patient with a contra-indication to the product(s) under evaluation.
  • Pregnant woman, birthing or breastfeeding mother
  • Minor (not emancipated)
  • Incapacitated person

Who the study is looking for

  • Patient of both sexes aged 18 or over.
  • Outpatient with unipolar depression (regardless of the time of the episode) (major depressive disorder).
  • Patient with an episode of major depression supported by PHQ-9 score greater than or equal to 5.
  • Patient with an episode of major depression supported by MADRS score greater than or equal to 7.
  • Patient accustomed to regular use of a smartphone and/or computer
  • Patient who, in the opinion of the investigator, will comply with the requirements of the protocol.
  • Patient affiliated to a social security scheme or beneficiary of such a scheme.
  • Patient who has received full information about how the clinical investigation shall be conducted and has signed an informed consent form.
  • Patient who reads and understands French.
  • Patient who has undergone clinical screening adapted to the clinical investigation.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (11)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Private psychiatric practice
Coordinator of this site? Confirm its status
AgenFranceRecruiting
Private psychiatric pratice
Coordinator of this site? Confirm its status
CaenFranceRecruiting
Centre Psychothérapique de Nancy
Coordinator of this site? Confirm its status
LaxouFranceNot yet recruiting
Private psychiatric practice
Coordinator of this site? Confirm its status
MaxévilleFranceTerminated
Private psychiatric practice
Coordinator of this site? Confirm its status
NantesFranceRecruiting
Centre Hospitalier Universitaire de Nantes
Coordinator of this site? Confirm its status
NantesFranceNot yet recruiting
Private psychiatric practice
Coordinator of this site? Confirm its status
ParisFranceNot yet recruiting
Private psychiatric practice
Coordinator of this site? Confirm its status
ReimsFranceNot yet recruiting
Centre hospitalier Guillaume Régnier
Coordinator of this site? Confirm its status
RennesFranceRecruiting
Private psychiatric practice
Coordinator of this site? Confirm its status
Saint-GrégoireFranceRecruiting
Private psychiatric practice
Coordinator of this site? Confirm its status
Saint-NazaireFranceRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.